Prenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARR
Rhea-AI Summary
Prenetics (NASDAQ: PRE) completed the divestment of ACT for $72 million, receiving $39.9 million in cash upfront and an additional $6.3 million held in escrow payable over 18 months, bringing total transaction proceeds to $46 million. The company says this lifts cash reserves to over $60 million (excluding Bitcoin) and leaves Prenetics debt-free. Prenetics is reallocating resources to its consumer health brand IM8, which is on pace to reach an $100 million ARR within its first 12 months. The company also reports a Bitcoin treasury of 255.4 BTC valued at $31.6 million (investment cost $27.8 million), an unrealized profit of $3.86 million (13.9% return), and a 1 BTC/day purchase policy since August 1, 2025.
Positive
- Cash reserves exceed $60 million (excluding Bitcoin)
- Debt-free balance sheet after ACT divestment
- IM8 on pace for $100 million ARR within 12 months
- Bitcoin treasury of 255.4 BTC valued at $31.6M
Negative
- $6.3 million held in escrow payable over 18 months
- Exit from clinical diagnostics narrows business diversification
News Market Reaction 2 Alerts
On the day this news was published, PRE declined 4.01%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.7% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $187M at that time.
Data tracked by StockTitan Argus on the day of publication.
- Strengthens Balance Sheet with Over
$60 Million in Cash1, Excluding Bitcoin Treasury - David Beckham Co-Founded IM8 on Track to Achieve
$100 Million ARR in First Year, Becoming One of the Fastest-Growing Supplement Brands in the History of the Industry - Bitcoin Treasury Grows to 255 BTC with 1 BTC Per Day Purchase Strategy Since August, NAV now at
$31.6 Million , with an unrealized profit of$3.86 Million
CHARLOTTE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, today announced the official completion of its divestment of ACT Genomics Co., Ltd. (“ACT”) to Delta Electronics, Inc. (TWSE:2308). This transaction marks a final step in Prenetics’ strategic exit from the clinical diagnostics sector, enabling the company to dedicate its resources and attention to its rapidly expanding consumer health initiatives.
The divestment significantly strengthens Prenetics' financial position. Based on its ownership percentage, Prenetics has received
The strategic shift allows Prenetics to fully capitalize on the remarkable momentum of IM8, which is on pace to achieve an annualized revenue run-rate (ARR) of
In addition to its robust cash position, Prenetics also provided an update on its Bitcoin treasury strategy. The company now holds 255.4 BTC, with a current portfolio value of
"The completion of the ACT divestment represents a pivotal transformation for Prenetics," said Danny Yeung, CEO and Co-Founder of Prenetics. "We have successfully streamlined our operations to focus entirely on our high-growth consumer health business, while building a very healthy balance sheet. With over
About Prenetics
Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, one of the World’s fastest growing supplement brands, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first consumer healthcare company to establish a Bitcoin treasury with its initial
Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar statements. Prenetics may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Prenetics’ beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not to the following: the Company’s ability to execute its strategies, manage its growth, and achieve and maintain profitability; the Company’s ability to develop and commercialize its products and services; the Company’s ability to maintain and enhance its brand; the Company’s ability to compete effectively; the Company’s ability to continue to develop and maintain relationships with its partners and customers; the Company’s ability to protect its intellectual property; the Company’s ability to comply with applicable laws and regulations; and the Company’s ability to obtain additional financing. Further information regarding these and other risks is included in Prenetics’ filings with the SEC. All information provided in this press release is as of the date of this press release, and Prenetics does not undertake any duty to update such information, except as required under applicable law.
1. Total cash reserves assuming full settlement of transaction proceeds